The United Kingdom and the United States have agreed to a important trade agreement that will preserve zero tariffs on British pharmaceutical shipments going into the American market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to increase funding on pharmaceuticals through the NHS. This pledge secures that duties on these crucial exports will remain at nothing for a duration of the next three years.
This deal comes after recent statements to significantly raise import taxes on branded drug products, with potential rates floated as high as double the cost.
"This arrangement with the United Kingdom strengthens the worldwide climate for cutting-edge drugs and brings long-overdue equity to transatlantic medicine commerce," a statement noted.
Economic Impact
Drugs are one of the UK's most significant goods shipped to the America, which is clearly the primary buyer for leading companies like GSK and AstraZeneca.
Trade data indicate that in the year to the end of September, the UK exported drugs totaling billions to the US. This amount represented nearly one-fifth of all goods exports in that period.
"This agreement secures employment, stimulates investment and facilitates the UK to emerge as a global hub for life sciences," the Business and Trade Secretary remarked.
Detailed British Pledges
The deal entails several notable commitments from the United Kingdom:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new treatments to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a aim to double total NHS spending on drugs from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The sum drug companies must return to the NHS to stay within budget will be limited at fifteen percent. Previously, repayments were more than twenty percent.
Industry Background
This agreement follows a protracted tension between the sector and the UK government over spending levels and approval rates.
These tensions were exacerbated by arguments that US consumers were paying a premium for the identical medicines than consumers in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been halted or cancelled, while multi-billion-dollar investments have been announced toward projects in the United States.
The Science Minister stated that the NHS needed to spend more on medicines, noting that its expenditure on drugs had decreased as a proportion of its overall budget over the last ten years.
